Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
MENLO PARK, Calif., Jan. 26, 2016 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. Eastern time.
A live audio broadcast of Corium’s presentation may be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.coriumgroup.com. A webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience in advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Crest® Whitestrips is a registered trademark of The Procter & Gamble Company.
Investor and Media Contact: Karen L. Bergman BCC Partners [email protected] (650) 575-1509
